866-997-4948(US-Canada Toll Free)

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 294 Pages

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Relapsed Chronic Lymphocytic Leukemia (CLL) Pipeline Review, H2 2016, provides an overview of the Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape.

Relapsed chronic lymphocytic leukemia (CLL) is a type of cancer chronic lymphocytic leukemia, that the cancer has come back after remission was achieved with treatment. Symptoms include weakness, feeling tired, weight loss, fever, night sweats and enlarged lymph nodes, pain or a sense of fullness in the belly which is caused by an enlarged spleen.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Relapsed Chronic Lymphocytic Leukemia (CLL) Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 3, 21, 20 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.Relapsed Chronic Lymphocytic Leukemia (CLL).

Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Relapsed Chronic Lymphocytic Leukemia (CLL) Overview 8
Therapeutics Development 9
Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Overview 9
Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis 10
Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies 11
Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes 13
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies 17
Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes 20
Relapsed Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 21
4SC AG 21
AbbVie Inc 22
Aptevo Therapeutics Inc 23
Astellas Pharma Inc. 24
Astex Pharmaceuticals Inc 25
Boehringer Ingelheim GmbH 26
Bristol-Myers Squibb Company 27
Celgene Corporation 28
Cellular Biomedicine Group, Inc. 29
Cyclacel Pharmaceuticals, Inc. 30
F. Hoffmann-La Roche Ltd. 31
Gilead Sciences, Inc. 32
Hutchison MediPharma Limited 33
ImmunoGen, Inc. 34
Immunomedics, Inc. 35
Incyte Corporation 36
Innate Pharma S.A. 37
Juno Therapeutics Inc. 38
Karyopharm Therapeutics, Inc. 39
LFB S.A. 40
Lymphocyte Activation Technologies, S.A. 41
Millennium Pharmaceuticals Inc 42
MorphoSys AG 43
Novartis AG 44
Oncternal Therapeutics, Inc. 45
Ono Pharmaceutical Co., Ltd. 46
PIQUR Therapeutics AG 47
Rhizen Pharmaceuticals S.A. 48
Sanofi 49
TRACON Pharmaceuticals Inc 50
Tragara Pharmaceuticals, Inc. 51
Verastem, Inc. 52
Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 53
Assessment by Monotherapy Products 53
Assessment by Combination Products 54
Assessment by Target 55
Assessment by Mechanism of Action 58
Assessment by Route of Administration 61
Assessment by Molecule Type 63
Drug Profiles 65
(dezapelisib + itacitinib adipate) - Drug Profile 65
4SC-202 - Drug Profile 66
acalabrutinib - Drug Profile 68
ACP-319 - Drug Profile 71
afuresertib hydrochloride - Drug Profile 72
AGS-67E - Drug Profile 75
AT-7519 - Drug Profile 77
atezolizumab - Drug Profile 80
BI-836826 - Drug Profile 94
BMS-986016 - Drug Profile 96
buparlisib hydrochloride - Drug Profile 98
CBM-C19.1 - Drug Profile 103
CC-122 - Drug Profile 104
Cellular Immunotherapy for Chronic Lymphocytic Leukaemia - Drug Profile 106
Cellular Immunotherapy to Target Receptor Tyrosine Kinase-Like Orphan Receptor 1 for Chronic Lymphocytic Leukemia - Drug Profile 107
duvelisib - Drug Profile 108
HMPL-523 - Drug Profile 119
idelalisib - Drug Profile 121
IMGN-529 - Drug Profile 129
IMMU-114 - Drug Profile 131
JCAR-014 - Drug Profile 133
JCAR-015 - Drug Profile 136
lirilumab - Drug Profile 141
monalizumab - Drug Profile 145
MOR-208 - Drug Profile 148
nivolumab - Drug Profile 153
obinutuzumab - Drug Profile 182
ofatumumab - Drug Profile 189
otlertuzumab - Drug Profile 197
PCAR-019 - Drug Profile 200
PCAR-119 - Drug Profile 201
pilaralisib - Drug Profile 202
PNK-007 - Drug Profile 204
PQR-309 - Drug Profile 205
S-055746 - Drug Profile 207
sapacitabine - Drug Profile 208
selinexor - Drug Profile 214
spebrutinib besylate - Drug Profile 233
TAK-659 - Drug Profile 235
TG-02 - Drug Profile 236
TGR-1202 - Drug Profile 239
tisagenlecleucel-T - Drug Profile 246
TRC-102 - Drug Profile 251
ublituximab - Drug Profile 253
UC-961 - Drug Profile 260
ulocuplumab - Drug Profile 262
urelumab - Drug Profile 263
venetoclax - Drug Profile 265
Relapsed Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 274
Relapsed Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 276
Relapsed Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 277
Featured News & Press Releases 277
Appendix 289
Methodology 289
Coverage 289
Secondary Research 289
Primary Research 289
Expert Panel Validation 289
Contact Us 289
Disclaimer 290

List of Tables
Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL), H2 2016 13
Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H2 2016 14
Number of Products under Development by Companies, H2 2016 15
Number of Products under Development by Companies, H2 2016 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2016 17
Comparative Analysis by Late Stage Development, H2 2016 18
Comparative Analysis by Clinical Stage Development, H2 2016 19
Comparative Analysis by Early Stage Development, H2 2016 20
Products under Development by Companies, H2 2016 21
Products under Development by Companies, H2 2016 (Contd..1) 22
Products under Development by Companies, H2 2016 (Contd..2) 23
Products under Investigation by Universities/Institutes, H2 2016 24
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H2 2016 25
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc, H2 2016 26
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aptevo Therapeutics Inc, H2 2016 27
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc., H2 2016 28
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals Inc, H2 2016 29
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H2 2016 30
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Company, H2 2016 31
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corporation, H2 2016 32
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellular Biomedicine Group, Inc., H2 2016 33
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2016 34
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 35
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Gilead Sciences, Inc., H2 2016 36
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hutchison MediPharma Limited, H2 2016 37
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by ImmunoGen, Inc., H2 2016 38
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics, Inc., H2 2016 39
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Incyte Corporation, H2 2016 40
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innate Pharma S.A., H2 2016 41
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Juno Therapeutics Inc., H2 2016 42
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 43
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB S.A., H2 2016 44
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lymphocyte Activation Technologies, S.A., H2 2016 45
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 46
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by MorphoSys AG, H2 2016 47
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Novartis AG, H2 2016 48
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Oncternal Therapeutics, Inc., H2 2016 49
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 50
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by PIQUR Therapeutics AG, H2 2016 51
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016 52
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sanofi, H2 2016 53
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by TRACON Pharmaceuticals Inc, H2 2016 54
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tragara Pharmaceuticals, Inc., H2 2016 55
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Verastem, Inc., H2 2016 56
Assessment by Monotherapy Products, H2 2016 57
Assessment by Combination Products, H2 2016 58
Number of Products by Stage and Target, H2 2016 60
Number of Products by Stage and Mechanism of Action, H2 2016 63
Number of Products by Stage and Route of Administration, H2 2016 66
Number of Products by Stage and Molecule Type, H2 2016 68
Relapsed Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H2 2016 278
Relapsed Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..1), H2 2016 279
Relapsed Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H2 2016 280

List of Figures
Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL), H2 2016 13
Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H2 2016 14
Number of Products under Development by Companies, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 18
Comparative Analysis by Clinical Stage Development, H2 2016 19
Assessment by Monotherapy Products, H2 2016 57
Number of Products by Top 10 Targets, H2 2016 59
Number of Products by Stage and Top 10 Targets, H2 2016 59
Number of Products by Top 10 Mechanism of Actions, H2 2016 62
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 62
Number of Products by Routes of Administration, H2 2016 65
Number of Products by Stage and Routes of Administration, H2 2016 65
Number of Products by Molecule Types, H2 2016 67
Number of Products by Stage and Molecule Types, H2 2016 67

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *